PRESS RELEASE Investor Contact Jason Starr Gen Gen IR@GenDigital.com Press@GenDigital.com Media Contact Audra Proctor TEMPE, Ariz. & PRAGUE, August 7, 2025 – Gen Digital Inc. (NASDAQ: GEN), a global leader dedicated to powering Digital Freedom, released its results for its first quarter fiscal year 2026, which ended July 4, 2025. • Revenue of $1,257 million, up 30% • Operating income of $446 million, up 7% • Operating margin of 36%, down 7 points • Diluted EPS of $0.22, down 25% • Operating cash flow of $40 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38793 INMUNE BIO INC. (Exact name of registrant as specified in its charter) (State of incorporation) (I.R.S. Employer Identification No.) 225 NE Mizner Blvd., Su ...

Doximity Announces Fiscal 2026 First Quarter Financial Results Total revenues of $145.9 million, up 15% year-over-year Operating cash flow of $62.1 million, up 51% year-over-year Free cash flow of $60.1 million, up 52% year-over-year Exhibit 99.1 SAN FRANCISCO, Calif., August 7, 2025 -- Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 first quarter ended June 30, 2025. "We began our year with strong profit growth and record ...

New York, August 7, 2025: Flutter Entertainment (NYSE: FLUT; LSE: FLTR) ("Flutter") the world's leading online sports betting and iGaming operator today announces Q2 results, and increased 2025 guidance. Key financial highlights: Exhibit 99.1 | In $ millions except where stated otherwise | | Three months ended June 30, | | | --- | --- | --- | --- | | | 2025 | 2024 | YOY | | Average monthly players (AMPs) ('000s)1 | 15,978 | 14,344 | +11% | | Revenue | 4,187 | 3,611 | +16% | | Net income | 37 | 297 | (88)% | ...

While ROI on this can be hard to measure, independent brand awareness surveys are already showing 50% gains in our target demographics – and 350% gains in the highly coveted 18-24 demographic, the trendsetters of the future. We couldn't possibly be more pleased with the result of this major bet taken years ago, which we expect to benefit us for years to come. To prepare for this, and in recognition of F1's global appeal, we spent the last quarter strengthening our international offering: Beyond F1 and inter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 29, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-35625 BLOOMIN' BRANDS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of ...

Exhibit 99.1 Teknova Reports Second Quarter 2025 Financial Results Matt Lowell, Teknova's Chief Financial Officer, added, "Compared to 2024, we delivered 7% revenue growth in the second quarter 2025 along with significant improvements in adjusted EBITDA and free cash outflow. We believe the Company is well positioned to maintain its momentum. We therefore reiterate our 2025 revenue guidance of $39-42 million and continue to anticipate full-year free cash outflow of less than $12 million," he explained. Corp ...

PART I. FINANCIAL INFORMATION [Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) The company's financial statements show increased assets, continued net losses, and sufficient liquidity, primarily from equity offerings Condensed Consolidated Balance Sheet Data (in thousands) | Balance Sheet Items | June 30, 2025 (unaudited) | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $17,220 | $11,055 | | Total current assets | $87,492 | $81,954 | | **Total assets** | **$101,534** | **$96,830** | | Total current liabilities | $15,531 | $14,967 | | **Total liabilities** | **$26,878** | **$26,998** | | **Total stockholders' equity** | **$74,656** | **$69,832** | | Accumulated deficit | ($566,457) | ($532,046) | Condensed Consolidated Statements of Operations Data (in thousands, except per share data) | Income Statement Items | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Total revenues | $— | $— | $— | $235 | | Research and development | $15,384 | $13,973 | $27,198 | $27,337 | | General and administrative | $4,929 | $3,342 | $8,888 | $6,849 | | **Loss from operations** | **($20,313)** | **($17,315)** | **($36,086)** | **($33,951)** | | **Net loss attributable to aTyr** | **($19,531)** | **($16,306)** | **($34,411)** | **($31,797)** | | Net loss per share, basic and diluted | ($0.22) | ($0.23) | ($0.39) | ($0.46) | Condensed Consolidated Statements of Cash Flows Data (in thousands) | Cash Flow Items | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | ($29,314) | ($42,829) | | Net cash (used in) provided by investing activities | ($1,119) | $5,372 | | Net cash provided by financing activities | $36,525 | $21,130 | | **Net change in cash, cash equivalents and restricted cash** | **$6,092** | **($16,327)** | - The company has incurred net losses since its inception in 2005, with an accumulated deficit of **$566.5 million** as of June 30, 2025[26](index=26&type=chunk) - Management believes that existing cash, cash equivalents, restricted cash, and available-for-sale investments of **$83.2 million** as of June 30, 2025, will be sufficient to meet material cash requirements for at least one year from the filing date of this report[28](index=28&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=22&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's clinical-stage pipeline, financial performance, and funding strategies, with key updates on efzofitimod [Overview](index=22&type=section&id=Overview) aTyr Pharma is a clinical-stage biotech advancing efzofitimod for ILD, with Phase 3 data expected soon, and other preclinical candidates - The lead therapeutic candidate is **efzofitimod**, a first-in-class biologic immunomodulator for treating interstitial lung disease (ILD)[70](index=70&type=chunk) - The global pivotal Phase 3 EFZO-FIT study for pulmonary sarcoidosis completed enrollment of 268 subjects in July 2024 and the last patient visit was completed in July 2025, with topline data expected in **mid-September 2025**[74](index=74&type=chunk) - The Phase 2 EFZO-CONNECT study in patients with SSc-ILD is ongoing, with interim data in June 2025 showing clinically important improvement in skin scores for **three of four** efzofitimod-treated patients[76](index=76&type=chunk) - The collaboration with Kyorin for efzofitimod in Japan has generated **$20.0 million** in payments to date, with up to an additional **$155.0 million** in potential milestones, plus royalties[77](index=77&type=chunk) [Liquidity and Capital Resources](index=26&type=section&id=Liquidity%20and%20Capital%20Resources) The company's liquidity, accumulated deficit, and funding sources are discussed, highlighting reliance on equity offerings and changes in cash flow from operations - As of June 30, 2025, the company had cash, cash equivalents, restricted cash, and available-for-sale investments of **$83.2 million** and an accumulated deficit of **$566.5 million**[82](index=82&type=chunk) - The company sold **8,771,725 shares** of common stock for net proceeds of approximately **$36.7 million** under its ATM Offering Program during the six months ended June 30, 2025[85](index=85&type=chunk) Summary of Net Cash Flow (in thousands) | Period | Net Cash Used in Operating Activities | Net Cash (Used in)/Provided by Investing Activities | Net Cash Provided by Financing Activities | | :--- | :--- | :--- | :--- | | **Six Months Ended June 30, 2025** | $(29,314) | $(1,119) | $36,525 | | **Six Months Ended June 30, 2024** | $(42,829) | $5,372 | $21,130 | - The decrease in net cash used in operating activities in H1 2025 compared to H1 2024 was primarily due to the timing of certain upfront efzofitimod manufacturing payments made in 2024[87](index=87&type=chunk) [Results of Operations](index=34&type=section&id=Results%20of%20Operations) Operating expenses increased in Q2 2025 due to higher R&D and G&A costs, with similar trends for the first six months, and further increases are anticipated Comparison of Operating Expenses for the Three Months Ended June 30 (in thousands) | Expense Category | 2025 | 2024 | Increase / (Decrease) | | :--- | :--- | :--- | :--- | | **Total research and development expenses** | **$15,384** | **$13,973** | **$1,411** | | **Total general and administrative expenses** | **$4,929** | **$3,342** | **$1,587** | - The **$1.4 million** increase in Q2 2025 R&D expenses was primarily due to a **$1.0 million** increase in manufacturing costs for a potential BLA filing for efzofitimod[107](index=107&type=chunk) - The **$1.6 million** increase in Q2 2025 G&A expenses was mainly due to a **$1.2 million** increase in personnel and pre-commercialization costs[108](index=108&type=chunk) Comparison of Operating Expenses for the Six Months Ended June 30 (in thousands) | Expense Category | 2025 | 2024 | Increase / (Decrease) | | :--- | :--- | :--- | :--- | | **Total research and development expenses** | **$27,198** | **$27,337** | **($139)** | | **Total general and administrative expenses** | **$8,888** | **$6,849** | **$2,039** | [Quantitative and Qualitative Disclosures About Market Risk](index=35&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company states that this item is not applicable - Not applicable[116](index=116&type=chunk) [Controls and Procedures](index=35&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective at a reasonable assurance level as of the end of the quarter, with no material changes identified - Based on an evaluation as of the end of the quarter, the Principal Executive Officer and Principal Financial Officer concluded that the company's disclosure controls and procedures were effective at a reasonable assurance level[118](index=118&type=chunk) - No changes in internal control over financial reporting were identified during the quarter that have materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[119](index=119&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=37&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently a party to any material legal proceedings, though it may face routine claims in the ordinary course of business - aTyr Pharma is not a party to any material legal proceedings at this time[121](index=121&type=chunk) [Risk Factors](index=37&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant risks related to clinical trial success, manufacturing, capital requirements, third-party collaborations, and market volatility - The company may face substantial delays in clinical trials and may fail to demonstrate safety and efficacy, particularly for the EFZO-FIT study, as there is no established FDA regulatory pathway for approval of a drug in pulmonary sarcoidosis[123](index=123&type=chunk)[133](index=133&type=chunk) - The company faces risks of manufacturing stoppages and challenges with its CDMOs, which could affect the clinical or commercial manufacture of its product candidates and regulatory activities required for a BLA submission[123](index=123&type=chunk)[146](index=146&type=chunk) - The company has a history of significant losses and will need to raise additional capital to fund operations, which may not be available on favorable terms or at all[123](index=123&type=chunk)[179](index=179&type=chunk) - The company depends on its collaboration with Kyorin for the development and commercialization of efzofitimod in Japan, and if this collaboration is not successful, the market potential may not be realized[126](index=126&type=chunk)[191](index=191&type=chunk) - The market price of the company's common stock has been and is likely to continue to be highly volatile[126](index=126&type=chunk)[295](index=295&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=105&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities during the period - None[345](index=345&type=chunk) [Defaults Upon Senior Securities](index=105&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities - None[346](index=346&type=chunk) [Mine Safety Disclosures](index=105&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[347](index=347&type=chunk) [Other Information](index=105&type=section&id=Item%205.%20Other%20Information) During the quarter, the Chief Financial Officer and General Counsel adopted Rule 10b5-1 trading plans for pre-arranged security sales Executive Trading Arrangements (Rule 10b5-1) | Name and Title | Action | Adoption Date | Total Shares to be Sold (Max) | Expiration Date | | :--- | :--- | :--- | :--- | :--- | | Jill M. Broadfoot, Chief Financial Officer | Adoption | 6/16/2025 | 252,514 | 6/16/2026 | | Nancy E. Denyes, General Counsel | Adoption | 6/13/2025 | 100,000 | 6/13/2026 | [Exhibits](index=106&type=section&id=Item%206.%20Exhibits) This section provides an index of exhibits filed with the Quarterly Report on Form 10-Q, including corporate governance and certification documents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 20-3435077 (State or other jurisdiction ...

IRVINE, Calif., August 7, 2025 – Xponential Fitness, Inc. (NYSE: XPOF) ("Xponential" or the "Company"), one of the leading global franchisors of boutique health and wellness brands, today reported financial results for the second quarter ended June 30, 2025. All financial data included in this release refer to global numbers, unless otherwise noted. All KPI information is presented on an adjusted basis to include full historical data for all brands in the brand portfolio as of June 30, 2025, and to exclude ...